24 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

D2.437 - Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema

Thumbnail

D2.436 - Application Study on the prevention and treatment of spleen aminopeptide oral solution on seasonal allergic rhinitis

Thumbnail

D2.438 - Adipose-derived stem cells secretome attenuates eosinophilic inflammation in a chronic rhinosinusitis with nasal polyps mouse model

Thumbnail

D2.439 - Low vitamin D levels in patients with allergic rhinitis and its supplementation

Thumbnail

D2.440 - Burden of disease and patient preference in Hereditary Angioedema: findings from a mixed methods survey of carers and patients in the United Kingdom

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series